DK446684A - Farmaceutisk middel indeholdende et renset, afgiftet endotoksin i kombination med en pyridinoploeselig ekstrakt af en mikroorganisme - Google Patents

Farmaceutisk middel indeholdende et renset, afgiftet endotoksin i kombination med en pyridinoploeselig ekstrakt af en mikroorganisme Download PDF

Info

Publication number
DK446684A
DK446684A DK446684A DK446684A DK446684A DK 446684 A DK446684 A DK 446684A DK 446684 A DK446684 A DK 446684A DK 446684 A DK446684 A DK 446684A DK 446684 A DK446684 A DK 446684A
Authority
DK
Denmark
Prior art keywords
endotoxine
taxed
organism
pyridine
purified
Prior art date
Application number
DK446684A
Other languages
Danish (da)
English (en)
Other versions
DK446684D0 (da
Inventor
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of DK446684D0 publication Critical patent/DK446684D0/da
Publication of DK446684A publication Critical patent/DK446684A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
DK446684A 1983-09-23 1984-09-19 Farmaceutisk middel indeholdende et renset, afgiftet endotoksin i kombination med en pyridinoploeselig ekstrakt af en mikroorganisme DK446684A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use

Publications (2)

Publication Number Publication Date
DK446684D0 DK446684D0 (da) 1984-09-19
DK446684A true DK446684A (da) 1985-03-24

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
DK446684A DK446684A (da) 1983-09-23 1984-09-19 Farmaceutisk middel indeholdende et renset, afgiftet endotoksin i kombination med en pyridinoploeselig ekstrakt af en mikroorganisme

Country Status (23)

Country Link
US (1) US4663306A (enExample)
JP (1) JPS60120817A (enExample)
KR (1) KR870000843B1 (enExample)
AT (1) AT385659B (enExample)
AU (1) AU566234B2 (enExample)
BE (1) BE900650A (enExample)
CA (1) CA1244765A (enExample)
CH (1) CH664897A5 (enExample)
DE (1) DE3434766C2 (enExample)
DK (1) DK446684A (enExample)
ES (1) ES8608872A1 (enExample)
FI (1) FI843716L (enExample)
FR (1) FR2552326B1 (enExample)
GB (1) GB2149301B (enExample)
HU (1) HU192585B (enExample)
IL (1) IL73034A (enExample)
IN (1) IN157240B (enExample)
IT (1) IT1179444B (enExample)
NL (1) NL8402902A (enExample)
NO (1) NO843776L (enExample)
NZ (1) NZ209635A (enExample)
SE (1) SE8404707L (enExample)
ZA (1) ZA847405B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
DE69429521T2 (de) * 1993-08-27 2002-07-18 Vetrepharm, Inc. Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
KR100533576B1 (ko) 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
CA2337445A1 (en) 1998-07-16 2000-01-27 Sumitomo Pharmaceuticals Co., Ltd. Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
DE60036019T2 (de) * 1999-12-13 2008-05-29 Bioniche Life Sciences Inc., Belleville Synthetische oligonukleotide die therapeutisch nützlich sind
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
IL153826A0 (en) * 2000-07-11 2003-07-31 Bayer Ag Use of strains of the parapox ovis virus against organ fibrosis
CA2478106A1 (en) * 2002-03-05 2003-09-12 Cell-Medicine, Inc. Solidified tissue immunoadjuvant
AU2003254792A1 (en) * 2002-08-02 2004-02-23 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
WO2005023277A1 (fr) * 2003-09-05 2005-03-17 Shenyang Sunbellcom Bio-Pharmaceutical Co., Ltd. Composition a la base de squelettes de parois de cellules de nocardia rouge procede de preparation et son utilisation therapeutique pour traiter l'erosion cervicale
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN118979001A (zh) 2014-06-17 2024-11-19 皇冠实验室有限公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
US12703689B2 (en) * 2017-08-17 2026-08-11 University Of Delaware Furan based compositions and methods of making thereof
AU2021297215B2 (en) 2020-06-23 2026-08-13 Crown Laboratories, Inc. Probiotic skin formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (enExample) * 1972-06-20 1973-12-27
FR2269962B1 (enExample) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism

Also Published As

Publication number Publication date
DK446684D0 (da) 1984-09-19
HU192585B (en) 1987-06-29
ATA302384A (de) 1987-10-15
AU566234B2 (en) 1987-10-15
GB2149301B (en) 1988-06-22
AU3340084A (en) 1985-03-28
BE900650A (fr) 1985-03-21
CH664897A5 (de) 1988-04-15
NL8402902A (nl) 1985-04-16
ES8608872A1 (es) 1986-07-16
FR2552326B1 (fr) 1988-05-13
IT8448894A0 (it) 1984-09-24
JPS6254775B2 (enExample) 1987-11-17
GB8423993D0 (en) 1984-10-31
ZA847405B (en) 1985-05-29
FR2552326A1 (fr) 1985-03-29
SE8404707D0 (sv) 1984-09-20
DE3434766A1 (de) 1986-04-30
ES536167A0 (es) 1986-07-16
NO843776L (no) 1985-03-25
GB2149301A (en) 1985-06-12
KR870000843B1 (ko) 1987-04-25
FI843716A7 (fi) 1985-03-24
IL73034A (en) 1988-11-15
NZ209635A (en) 1989-01-27
DE3434766C2 (de) 1987-05-14
IN157240B (enExample) 1986-02-15
CA1244765A (en) 1988-11-15
JPS60120817A (ja) 1985-06-28
IT1179444B (it) 1987-09-16
US4663306A (en) 1987-05-05
KR850002404A (ko) 1985-05-13
FI843716L (fi) 1985-03-24
HUT35521A (en) 1985-07-29
FI843716A0 (fi) 1984-09-21
AT385659B (de) 1988-05-10
SE8404707L (sv) 1985-03-24

Similar Documents

Publication Publication Date Title
DK446684D0 (da) Farmaceutisk middel indeholdende et renset, afgiftet endotoksin i kombination med en pyridinoploeselig ekstrakt af en mikroorganisme
ES553764A0 (es) Un procedimiento para fabricar un articulo de una composicion fotopolimerizable.
DK569784A (da) Farmaceutisk baeremedium med forsinket virkning
IL71967A (en) Drug administration composition
SE8801813D0 (sv) Pharmaceutical composition
KR890701101A (ko) 제약학적 조성물
DK408788D0 (da) Fremstilling af terapeutiske ringe
GB8629223D0 (en) Replication of carriers
FI821240L (fi) Med dubbelmod fungerande maetaravlaesningsanordning
DK529885D0 (da) Farmaceutiske kapsler med langvarig frigivelse
PH21029A (en) Benzene derivatives, pharmaceutical compositions and method of use thereof
DK49488D0 (da) Anaestesi-praeparat
FI822670L (fi) Ergopeptinderivat, foerfaranden foer deras framstaellning, dessa innehaollande farmaceutiska kompositioner och deras anvaendning vid terapeutisk behandling
FI902673A7 (fi) Anti-inflammatoorisia ja analgeettisia yhdisteitä, niitä sisältäviä se oksia ja menetelmiä niiden valmistamiseksi sekä niiden käyttö
IT1182061B (it) Derivati di amminofenolo, procedimento per prepararli e composizione farmaceutica che li contiene
DK200586D0 (da) Anvendelse af pyridinonforbindelser med antithrombotisk virkning i laegemidler
DK369385D0 (da) Middel til behandling af schizofreni
KR890701577A (ko) 시토칼라신 정제법 및 조성물
SE8500553L (sv) Pharmaceutical composition
FI852699A7 (fi) Trisykliset dihydropyridatsinonit ja niitä sisältävät farmaseuttiset koostumukset.
GB8621771D0 (en) Composition to prevent smoking
FI853228L (fi) Nya -butyrolaktamer, deras farmaceutiskt aktiva kompositioner, foerfaranden foer deras framstaellning och deras anvaendning som laekemedel.
IL79120A0 (en) Glycerol derivatives,their manufacture and pharmaceutical compositions containing them
IL80448A (en) Purified tnf composition
IT1178915B (it) Composizione farmaceutica per rin forzare i vasi sanguigni

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment